Literature DB >> 11049767

Human herpesvirus 6 and multiple sclerosis: systemic active infections in patients with early disease.

K K Knox1, J H Brewer, J M Henry, D J Harrington, D R Carrigan.   

Abstract

By means of immunohistochemical staining, cells actively infected with human herpesvirus 6 (HHV-6) were found in central nervous system tissues from 8 (73%) of 11 patients with definite multiple sclerosis (MS). Interestingly, 17 (90%) of 19 tissue sections showing active demyelination were positive for HHV-6-infected cells compared with only 3 (13%) of 23 tissue sections free of active disease (P<.0001). Central nervous system tissues from 2 of 28 normal persons and patients with other inflammatory demyelinative diseases were positive for HHV-6-infected cells (P<.0001), and the 2 positive cases were diagnosed as having HHV-6 leukoencephalitis. By use of a rapid culture assay, blood samples from 22 (54%) of 41 patients with definite MS were found to contain active HHV-6 infections, compared with 0 of 61 normal controls (P<.0001). No significant difference was found between HHV-6 viremia-positive and HHV-6 viremia-negative MS patients with respect to type of disease (relapsing/remitting or progressive). In contrast, patients with active HHV-6 viremia were significantly younger and had shorter durations of disease than did HHV-6 viremia-negative patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11049767     DOI: 10.1086/318141

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

Review 1.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

Review 2.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Aptamer-conjugated nanoparticles for cancer cell detection.

Authors:  Colin D Medley; Suwussa Bamrungsap; Weihong Tan; Joshua E Smith
Journal:  Anal Chem       Date:  2011-01-10       Impact factor: 6.986

4.  Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls.

Authors:  Maria V Tejada-Simon; Ying C Q Zang; Jian Hong; Victor M Rivera; James M Killian; Jingwu Z Zhang
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Association of human herpesvirus 6 and human herpesvirus 7 with demyelinating diseases of the nervous system.

Authors:  V Tomsone; I Logina; A Millers; S Chapenko; S Kozireva; M Murovska
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

Review 6.  Human herpes virus 6B: a possible role in epilepsy?

Authors:  William H Theodore; Leon Epstein; William D Gaillard; Shlomo Shinnar; Mark S Wainwright; Steven Jacobson
Journal:  Epilepsia       Date:  2008-07-08       Impact factor: 5.864

7.  Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections.

Authors:  D Donati; N Akhyani; A Fogdell-Hahn; C Cermelli; R Cassiani-Ingoni; A Vortmeyer; J D Heiss; P Cogen; W D Gaillard; S Sato; W H Theodore; S Jacobson
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

Review 8.  Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.

Authors:  Anthony L Komaroff; Philip E Pellett; Steven Jacobson
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 9.  Viruses and multiple sclerosis.

Authors:  Jussi Oskari Virtanen; Steve Jacobson
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-08       Impact factor: 4.388

10.  Macrophage IL-12p70 signaling prevents HSV-1-induced CNS autoimmunity triggered by autoaggressive CD4+ Tregs.

Authors:  Kevin R Mott; David Gate; Mandana Zandian; Sariah J Allen; Naveen Kumar Rajasagi; Nico van Rooijen; Shuang Chen; Moshe Arditi; Barry T Rouse; Richard A Flavell; Terrence Town; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-08       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.